Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jul;11(4):383-7.
doi: 10.2217/FCA.15.48. Epub 2015 Aug 4.

Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?

Ana Barac  1
Affiliations

Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?

Ana Barac. Future Cardiol. 2015 Jul.
No abstract available

Keywords: biomarkers; cancer treatment; cardiac imaging; cardiotoxicity; cardiovascular outcomes; cardiovascular risk models; targeted therapeutics.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work was supported in part by NIH/5KL2TR000102-04 to A Barac. A Barac has received research support and honorarium for lectures from Genentech, Inc. and consultancy fees from Cell Therapeutics, Inc. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 2002;20(5):1215–1221. - PubMed
    1. Cote GM, Sawyer DB, Chabner BA. ERBB2 inhibition and heart failure. N. Engl. J. Med. 2012;367(22):2150–2153. - PubMed
    1. Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin. Oncol. 2001;28(1 Suppl. 3):20–27. - PubMed
    1. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 2012;30(31):3792–3799. - PMC - PubMed
    1. Kumler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat. Rev. 2014;40(2):259–270. - PubMed

Publication types

LinkOut - more resources